- Details
- In this conversation with Charles Ryan, MD, Mack Roach III, MD discusses radiotherapy options for patients with clinically node-positive prostate cancer. In particularly with oligometastatic disease we are seeing long-term follow-up from a number of trials and have begun integrating data from these trials into clinical practice. Biographies: Mack Roach III, MD, Professor of Radiation Oncology and...
|
- Details
- In this conversation with Charles Ryan, Mark Rubin highlights the key points he addresses in his 2019 Advanced Prostate Cancer Consensus Conference presentation where he speaks about the future of biomarkers in advanced prostate cancer. Biographies: Mark A. Rubin, MD, Professor, Principal Investigator, and Director Department for BioMedical Research (DBMR), University of Bern, Switzerland. Dr. Rub...
|
- Details
- Mack Roach presents on radiotherapy options for patients with clinically node-positive prostate cancer at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Dr. Roach touches on areas such as the optimal candidate for salvage lymph node dissection (SLND) for nodal recurrence of prostate cancer, the role of adding ADT to radiotherapy, and the NRG/RTOG 9413 study which showed whole pelv...
|
- Details
- Karim Fizazi summarizes how best to treat node-positive (cN+) prostate cancer patients at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). There are over 20 randomized controlled trials in localized and advanced prostate cancer that have been published according to Dr. Fizazi, yet he notes, none have been published in the setting of node-positive prostate cancer. In this presentatio...
|
- Details
- Christopher Logothetis presents on the ethnicity and prognosis of prostate cancer during the Regional Care (Demographic and Environmental Factors) Session at the Advanced Prostate Cancer Consensus Conference the (APCCC 2019). Dr. Logothetis discusses the significant difference in the incidence and mortality of prostate cancer worldwide. There are greater differences in the incidence rates than in...
|
- Details
- Martin Gleave presents on the topic of testosterone measurement and its various nuances in the context of advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Testosterone measurement is important as androgens are the drivers of activity of the androgen receptor. Dr. Gleave supports the periodic assessment of testosterone levels to ensure castrate levels, wit...
|
- Details
- Joe O'Sullivan presented on the aging population and how to properly assess them in the context of prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The age at diagnosis of prostate cancer has been increasing over time, while prostate cancer mortality has been decreasing. Aging is associated with increased comorbidities, which may affect the tolerance of therapies...
|
- Details
- In this presentation, Mark Frydenberg presents the topic of hot flushes caused by androgen deprivation therapy (ADT) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Hot flushes are defined as a subjective feeling of warmth in the upper torso, followed by excessive perspiration. Dr. Frydenberg focuses on the various treatment options for hot flushes, including medical treatments...
|
- Details
- Inge van Oort presented the topic of managing sexuality and incontinence issues in patients with advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). When assessing sexual symptoms she references the EAU guidelines on sexual activity and the percentage of prostate cancer patients that will receive androgen deprivation therapy (ADT) at some point in the diseas...
|
- Details
- In this presentation, Susan Halabi discusses the implications of subgroup analyses in metastatic castration-resistant prostate cancer (mCRPC) trials during the management of CRPC session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. The challenge, according to Dr. Halabi, is balancing the dichotomy of the danger of interpreting subgroup analysis with applying overall results o...
|
